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ChREBP binding to fatty acid synthase and L-type
pyruvate kinase genes is stimulated by glucose in
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Gabriela da Silva Xavier,1,† Guy A. Rutter,1,† Fre´de´rique Diraison,* Chrysovalantis Andreolas,*
and Isabelle Leclerc2,†
From the Henry Wellcome Laboratories for Integrated Cell Signalling,* Department of Biochemistry,
University of Bristol, Bristol, BS8 1TD; and Section of Cell Biology,† Division of Medicine, Imperial College,
Exhibition Road, London SW7 2AZ, UK
Abstract Pancreatic b-cell dysfunction is central to the
pathogenesis of type 2 diabetes and may involve secretory
failure through glucolipotoxity. The relative importance of the
transcription factors carbohydrate-responsive element bind-
ing protein (ChREBP), sterol-responsive element binding
protein-1c (SREBP-1c), andupstream stimulatory factor (USF)
in the induction of lipogenic genes by glucose remains unclear.
By confocal imaging, we show that ChREBP translocates to the
nucleus in MIN6 b cells in response to glucose. Both ChREBP
andSREBP-1cwere required for the induction of the fatty acid
synthase (FAS) promoter by glucose, and chromatin immuno-
precipitation (ChIP) assay revealed that glucose induced the
binding of both ChREBP and SREBP-1c to the FAS promoter
without affecting USF2 binding. By contrast, ChIP assay re-
vealed that high glucose prompted direct binding of ChREBP,
but not SREBP-1c or USF2, to the liver-type pyruvate kinase
(L-PK) promoter. This event was indispensable for the in-
duction of the L-PK gene by glucose, as demonstrated by RNA
silencing, single-cell promoter analysis, and quantitative real-
time PCR. We conclude that ChREBP is a critical regulator
of lipogenic genes in the b cell and may play a role in the
development of glucolipotoxicity and b cell failure through
alteration of gene expression in type 2 diabetes.—da Silva
Xavier, G., G. A. Rutter, F. Diraison, C. Andreolas, and I.
Leclerc. ChREBP binding to fatty acid synthase and L-type
pyruvate kinase genes is stimulated by glucose in pancreatic
b-cells. J. Lipid Res. 2006. 47: 2482–2491.
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chromatin immunoprecipitation
Carbohydrate response element binding protein (ChREBP,
also known as WBSCR14 or Mondo B) (1) is a recently
described transcription factor belonging to the basic helix-
loop-helix leucine zipper family (2), which regulates car-
bohydrate metabolism in the liver (3). Mice deleted for
both alleles of ChREBP (4) are glucose intolerant and in-
sulin resistant and have diminished rates of glycolysis and
lipogenesis. This results in high liver glycogen content, low
plasma free fatty acids levels, and reduced adipose tissue
mass. Plasma insulin levels are normal despite elevated
glucose concentrations, suggesting a defect in pancreatic
b cell glucose sensing and/or insulin secretion.
In hepatocytes, ChREBP activity is regulated acutely by a
series of phosphorylation/dephosphorylation reactions, al-
though this has recently been challenged (5). At low glucose
concentrations, ChREBP exists in an inactive, phosphory-
lated state in the cytosol. There are twomajor protein kinase
A (PKA) phosphorylation sites, the first located near the
nuclear localization signal at Ser196 and the second near the
DNA binding site at Thr666. Dephosphorylation of Ser196
allows ChREBP entry into the nucleus, whereas dephos-
phorylation of Thr666 allows DNA binding. AMP-activated
protein kinase (AMPK) also regulates ChREBP by phos-
phorylation of Ser568, a modification that diminishes its
DNA binding ability (6–8). Max-like protein X is the func-
tional heteromeric partner of ChREBP in regulating the
expression of glucose-responsive genes in hepatocytes (9).
Sustained hyperglycemia promotes fatty acid synthesis
and triglyceride accumulation in the b cell. This “gluco-
lipotoxicity” has been suggested by others (10), and our-
selves (11, 12), to contribute to insulin secretory defects
seen in type 2 diabetes. We have previously identified sterol-
responsive element binding protein-1c (SREBP-1c) as an
important transcription factor responsible for lipid accu-
mulation in pancreatic islets in response to high glucose
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through stimulation of acetyl-CoA carboxylase-1 (ACC1)
(11) and fatty acid synthase (FAS) (12) gene expression.
Because ChREBP is expressed in the pancreatic islets in
a glucose-inducible manner, and forced overexpression of
ChREBP in INS1 cells resulted in a left-shift of the liver-
type pyruvate kinase (L-PK) gene in response to glucose
(13), we have explored the role of ChREBP in the regu-
lation of lipogenic genes in the b cell using both inac-
tivation and overexpression strategies. Our results indicate
that ChREBP binds directly to the endogenous promoters
of the L-PK and FAS genes in a glucose-dependent but
insulin-independent manner in MIN6 cells and is abso-
lutely required for their induction by glucose. ChREBP is
therefore potentially involved in the alteration of gene
expression during the b cell compensation phase in the
early stage of type 2 diabetes and could contribute to the
development of b cell failure through lipoapoptosis.
MATERIALS AND METHODS
Materials
The Silencer small interfering RNA (siRNA) construction kit
was from Ambion (Huntingdon, UK). Primers for siRNA con-
struction and PCR were from MWG Biotech (Milton Keynes,
UK). TransITTM -TKO transfection reagent was from Mirus Corp.
(Madison, WI). Rat insulin radioimmunoasssay kit was from Linco
(St. Charles, MO). Tissue culture reagents were from Sigma-
Aldrich (Dorset, UK) or Gibco-BRL (Paisley, UK). Lipofectamine
2000TM and SYBR Green platinum were from Invitrogen (Paisley,
UK). Anti-upstream stimulatory factor-2 (anti-USF2) antibody
was a kind gift from Dr. Benoit Viollet (Institut Cochin, Paris).
Anti-SREBP-1c antibody was from Santa Cruz Biotechnology, Inc.
Other reagents were from Sigma or BDH.
Plasmids and adenoviruses
pChREBP was generated by RT-PCR fromMIN6 cell total RNA
using the following primers: 59-ATG GAA CAG AAG CTT ATT
TCT GAA GAA GAT CTT GCG CGC GCG CTG GCG GAT CTA
TCC GTG AAC-39 (c-myc sequence underlined) and 59-CGC GGA
GCT CTT ATA ATG GTC TCC CCA GGG TGC CCT CTG TGA
CTG C-39. The resulting cDNA was phosphorylated by T4 poly-
nucleotide kinase (Roche) and subcloned into pcDNA3 (Invi-
trogen) vector linearized with EcoRV. pFAS.LucFF was generated
by subcloning the XhoI fragment (2187 to 165) of the rat FAS
gene (14) into pGL3 basic (Promega) vector linearized with XhoI.
All the constructs were verified by DNA sequencing. pLPK.LucFF
has been described previously (15), and plasmids encoding con-
stitutively active and dominant-negative forms of SREBP-1c were
as described in (11). Adenovirus encoding for the SREBP-1c
dominant negative (SREBP-DN) control adenovirus expressing
green fluorescent protein alone, and the infection procedure
were as described (11).
Generation of anti-ChREBP antibody
Polyclonal anti-ChREBP antibody was generated in rabbits
immunized with a synthetic peptide corresponding to the C ter-
minus of mouse and rat ChREBP [(C)ATRAVTEGTLGRPL],
conjugated to keyhole limpet hemocyanin (KLH, Calbiochem)
using sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (Sulfo-SMCC; Pierce, Tattenhall, UK). Briefly, 10 mg
KLH was gently dissolved in 2 ml PBS on a wheel rotator before
the addition of 2 mg Sulfo-SMCC and left on the wheel rotator
for a further 3 h at room temperature. A Sephadex G-25 column
(PD-10, Pharmacia Biotech) was equilibrated with 25 ml PBS, and
the 2 ml KLH/Sulfo-SMCC mixture was loaded onto the column
and eluted with 3.5 ml PBS. ChREBP peptide antigen (2.5 mg)
was added to the eluate and left on a wheel rotator for 1 h at room
temperature and overnight at 4jC. A Sephadex G-25 column was
equilibrated with 25 ml H2O, loaded with the 3.5 ml peptide-
antigen mixture and eluted with 3.5 ml H2O. The resulting
conjugated peptide was stored at 20jC until further use. Im-
mediately before rabbit immunization, 1 ml of conjugated pep-
tide antigen was emulsified with an equal volume of Complete
Freund’s Adjuvant (Sigma). After taking preimmune serum from
the rabbits, 800 ml of the emulsion was injected per rabbit, sub-
cutaneously, at four different sites (200 ml/site) on the back, at
week 0. Three booster injections in which the peptide antigen
was emulsified with Incomplete Freund’s Adjuvant (Sigma) were
given as above at weeks 3, 6, and 9. Serum was taken at weeks 5
and 8, and a termination bleed was done at week 10. Purification
of total IgG fraction was performed using caprylic acid and ammo-
nium sulfate sequential precipitations, as described in (16).
MIN6 cell culture
Cells were cultured in a humidified atmosphere at 37jC with
5% CO2. MIN6 b cells (17) were used between passages 19 and 30
and grown in DMEM containing 15% (v/v) heat-inactivated fetal
calf serum, 25 mM glucose, 5.4 mM KCl, 2 mM glutamine, 25 mM
b-mercaptoethanol, 100 IU/ml1 penicillin, and 100 mg/ml1
streptomycin. MIN6 cells were seeded on poly-L-lysine-coated
coverslips prior to microinjection. Plasmids and siRNAs were
transfected into cells with Lipofectamine 2000TM and TransITTM-
TKO, respectively. Transduced cells were cultured in normal
medium for 48 h and further cultured in medium containing
3 mM glucose 16 h prior to experiments.
siRNA construction
siRNAs were generated using the Ambion Silencer siRNA con-
struction kit according to the manufacturer’s protocol. Starting
primerpairs weredesignedas suggested in theAmbionprotocol and
according to published guidelines (18–20). Sense and anti-sense
target sequences were derived from cDNA for ChREBP (GenBank
accessionnumberAB074517)with senseprimer sequence as follows:
508-AAACCTGAGGCTGTTGTCTTCCTGTCTC-527 (T7 promoter
sequence at the 39 end underlined), with the anti-sense primer
having the complimentary sequence. Control siRNAs were gener-
ated with primers derived by scrambling the siRNA sequence
for ChREBP, with the sense primer sequence as follows: AAGGC-
TGTTTCACCTGAGTTCCTGTCTC. All primer sequences were
subjected to BLAST searches to ensure that there were no matches
with known sequences of other genes.MIN6b cells were transfected
with siRNA at a final concentration of 0.5 nM, according to the
manufacturer’s instructions and as described in (21).
Western (immuno) blot analysis
Cells were washed twice in ice-cold PBS, scraped in ice-cold lysis
buffer (PBS, 1% Triton X-100, 5 mg/ml1 pepstatin, 5 mg/ml1
antipain, 5 mg/ml1 leupeptin, 2 mM benzamidine and 0.5 mM
dithiothreitol) and vortex-mixed. Protein content was assayed
usingaBCATM protein assay kit (Pierce; Rockford, IL), against BSA
Type V (Sigma) standards. Total protein extracts (50 mg) were
resolved by SDS-PAGE (10% w/v acrylamide) and transferred to
polyvinylidene difluoride membranes (Immobilon-P, Millipore),
followed by immunoblotting with anti-ChREBP antibody used at
1:1000. Anti-rabbit secondary antibody (Amersham) was revealed
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using BM chemiluminescence blotting substrate (Roche Diag-
nostics; Lewes, UK).
Single-cell reporter gene assay
Intranuclear microinjection of plasmids, antibodies, and
siRNAs was performed using an Eppendorf 5121/5246 micro-
manipulator at plasmid concentrations of 0.1 (pLPK.LucFF,
pPdx1.LucFF, and pFAS.LucFF)) and 0.05 (pCMV-RL) mg/ml
1,
and antibody against ChREBP and SREBP at 1 mg/ml1 as de-
scribed (15, 22). Antibody was injected into the nucleus and
cytosol of the cell. Individual experiments involved injection of
100–200 separate cells per condition, with an efficiency of 5–20%
productive injection as assessed by expression of Renilla reniformis
luciferase activity. MIN6 cells were imaged 6 h after microinjec-
tion and culture under the conditions described in the figure
legends. Photon counting imaging of firefly and R. reniformis lu-
ciferase activities was performed in single living cells using an
Olympus IX-70 inverted microscope (310 air objective, 0.4 NA)
and an intensifed charge-coupled device camera (Photek; East
Sussex, UK) as previously described (15, 23).
Insulin secretion
MIN6 cells, seeded in 6-well plates, were grown to 50% con-
fluency and transfected with control or anti-ChREBP siRNA for
48 h (see above). Culture was continued for 16 h in DMEM con-
taining 3 mM glucose. Cells were washed in PBS and incubated
in Krebs Ringer Bicarbonate (KRB) medium containing either
low (3 mM) or high (30 mM) glucose concentrations. Incuba-
tions were performed for 20 min at 37jC in a shaking water bath.
Total and released insulin was measured by radioimmuno-
assay (24).
Real-time RT-PCR
Total mRNA was isolated and specific messages quantified
using TaqManTM analysis as in (21), and TaqManTM primers and
internal probes or real-time primers (SYBR Green) for amplifi-
cation of FAS, b-actin, and cyclophilin were as described in (21)
and for L-PK as in (25).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed as described in
(26). MIN6 b cells were cultured in medium containing 3 mM
glucose for 16 h prior to stimulation with medium containing 3 or
30 mM glucose for 6 h prior to cross-linking with formaldehyde.
DNA-protein complexes were immunoprecipitated with antibodies
against ChREBP, SREBP-1c, and USF2 and then digested with
proteinase K. After phenol-chloroform extraction and ethanol pre-
cipitation of the resulting DNA, PCR was performed to amplify the
L-PK and FAS promoters. Theprimers used to amplify themouse L-
PK promoter from 392 to 194 bp were 59-AAGTCTGCTTTAAG-
TGGGGCT-39 and 59-TCCCCTCCAAGTTCCCTCCAT-39; for the
FAS promoter from 135 to 14 bp, 59-CGGCGCGCCGGG-
TCCCGGGG-39 and 59-CCGCGCCGGCGCTATTTAAA-39; and for
the FAS promoter from 360 to 222 bp, 59-CGCCCGACCCA-
CACTG-39 and 59-CGGACGAAGGCAGGGGC-39.
Measurement of triglyceride content
Cells were transfected with control or ChREBP siRNA for 48 h,
maintained for 16 h at 3 mM glucose, and then in 3 or 30 mM
glucose for 24 h before measuring triglycerides (TGs) and pro-
tein concentrations. Total lipids were extracted using chloro-
form-methanol (2:1; v/v) as in (27). Extracted lipids were air
dried, and 10 ml of a detergent (Thesit; Fluka, Gillingham,
Dorset, UK) was added to the dry pellet. Samples were air dried
again and resuspended in 50 ml H2O (28). TG was measured
using a commercial kit (InfinityTM Triglyceride Reagent, Sigma)
and a standard curve of triolein (Sigma) treated in parallel with
the samples. Protein concentration was determined using a BCA
kit (Pierce; Rockford, IL).
Immunocytochemistry
Cells were fixed in 4% (v/v) paraformaldeyhde and 0.3%
Triton X-100 and stained with anti-c -myc antibody (9E:10; 1:200),
and revealed with fluorescein-conjugated goat anti-mouse IgG
(Sigma) (22). Images were captured using a Leica SP2 laser
scanning confocal microscope (363 objective).
Statistical analysis
Data are given as means 6 SEM. Comparisons between means
were performed by unpaired one-tailed Student’s t-test with
Bonferroni correction as appropriate, using Microsoft Excel.
RESULTS
Elevated glucose concentrations cause nuclear
translocation of ChREBP in MIN6 bcells
To visualize the subcellular localization of ChREBP at low
and high glucose concentrations, the relatively well differ-
entiated b cell line MIN6 was transfected with c -myc-tagged
pChREBP expression vector and incubated for 24 h at 3mM
glucose and then at 30mMglucose for a further 16 and 24 h
before fixation and immunocytochemical analysis,Hoeschst
staining, and confocal imaging as described inMaterials and
Methods (Fig. 1A, B). The proportion of cells expressing
ChREBP in the nucleus increased from 31% to 55% after
16 h at high glucose and to 69% after 24 h.
ChREBP silencing decreases triglyceride content and
potentiates glucose-stimulated insulin secretion in
MIN6 cells
To determine the importance of ChREBP in the occur-
rence of glucolipotoxicity in MIN6 cells, ChREBP expres-
sion was silenced using siRNAs. ChREBP protein content
was decreased by 87.32 6 0.25% and 65.59 6 0.52% at
48 and 72 h, respectively, as assessed by Western blot
(Fig. 1C), and ChREBP message content was decreased by
.95% at 48 h as assessed by quantitative real-time RT-PCR
(Fig. 1D). ChREBP cellular depletion significantly de-
creased TG content at both 3 and 30 mM glucose
concentrations (Fig. 1E) and slightly enhanced secreted
insulin at 30 mM glucose (Fig. 1F).
Both ChREBP and SREBP-1c are required for
glucose-stimulated FAS gene expression in MIN6 cells
Given the decrease in MIN6 cellular TG content fol-
lowing ChREBP silencing (Fig. 1E), we next investigated
the relative importance of ChREBP versus SREBP-1c in the
regulation of lipogenic genes by glucose in this cell type.
Figure 2 shows that both ChREBP and SREBP-1c are
required for glucose-stimulated FAS gene expression in
single MIN6 cells. Thus, the glucose responsiveness of the
mouse FAS promoter was completely abolished following
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cellular microinjection of antibodies against either
ChREBP (Fig. 2A) or SREBP-1c (Fig. 2B) together with
pFAS.LucFF and pRL.CMV constructs. Similarly, glucose
induction of endogenous FAS mRNAs was inhibited in cell
populations following ChREBP silencing using siRNA
(Fig. 2C) or SREBP-1c inactivation with SREBP-1c-DN ade-
novirus (Fig. 2D).
Glucose promotes the binding of ChREBP and SREBP-1c
to the FAS promoter in vivo
Previous studies using SREBP-1/ knock-out mice have
shown the absolute requirement for this factor for the
induction of the FAS gene by fasting/refeeding in the liver
(29). Also, in USF1 and USF2/ knock-out mice, the
induction of FAS by fasting/refeeding was significantly
Fig. 1. Glucose regulates carbohydrate-responsive element binding protein (ChREBP) cellular localization
and expression in MIN6 cells. A: MIN6 cells were seeded on poly-L-lysine-coated coverslips and transfected
with pChREBP using Lipofectamine 2000TM. The cells were cultured in normal medium (25 mM glucose) for
24 h after transfection and then incubated in 3 mM glucose for 16 h and in either 3 or 30mM glucose for a
further 24 h, as indicated. ChREBP distribution and nuclear DNA were detected using anti-c -myc monoclonal
antibody and Hoechst 33258 staining, respectively, prior to confocal imaging and cell counting (see Materials
and Methods). B: Graphical representation of the experiment described in (A). C, D: MIN6 cells were
transfected with ChREBP specific and scrambled small interfering RNAs (siRNAs) using TransITTM-TKO and
cultured in normal medium for 48 h or 72 h, as indicated, before Western blotting (C), or for 48 h in normal
medium and 16 h in 3 mM glucose, followed with 6 h at 3 or 30 mM glucose, as indicated, before quantitative
real-time RT-PCR assay (D). E, F: MIN6 cells were cultured as in (C) and triglycerides content and insulin
secretion were performed as described in Materials and Methods. Data are means 6 SEM from a minimum
of three separate experiments. **P , 0.05 for the effect of specific versus scrambled siRNAs.
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impaired (30). To determine in the living pancreatic b cell
the respective roles of ChREBP, SREBP-1c, and USF in the
glucose responsiveness of the FAS gene, we performed
chromatin immunoprecipitation assays using cells incu-
bated at either low or high glucose concentrations and
anti-USF2, anti-SREBP-1c, or anti-ChREBP antibodies. In
the rat FAS lpromoter, because two E-boxes, located at
332 and 65 bp, bind USF in vitro (31), we used two sets
of PCR primers that would include these sites in the mouse
FAS promoter (arrows in Fig. 3A, B, left panels). As shown
in Fig. 3, USF2 bound at both 3 and 30 mM glucose, to
both the proximal and distal stretches of sequences in-
cluded in our chromatin immunoprecipitation (ChIP)
assay. On the other hand, SREBP-1c was bound to the
proximal stretch of sequence at high glucose concentra-
tions only. ChREBP, however, bound to both stretches of
the promoter in a strongly glucose-dependent manner
(Fig. 3A, B).
ChREBP, but not SREBP-1c, is responsible for the glucose
responsiveness of the L-PK gene in MIN6 cells
Inhibition of endogenous ChREBP through the intro-
duction of an antibody against ChREBP into MIN6 cells
by microinjection led to ablation of glucose-induced L-PK
promoter activity (Fig. 4A), whereas overexpression of the
wild-type protein did not cause a significant change at basal
glucose concentration but led to a 1.75 6 0.007-fold in-
crease at 30 mM glucose (Fig. 4B). ChREBP knockdown
by RNA silencing led to a concomitant ablation of glucose-
induced changes in L-PKmRNA levels (Fig. 4C), as assessed
by real-time quantitative RT-PCR. Because we have previ-
ously reported (32) that glucose induction of the L-PK
promoter in the pancreatic b cell was secondary to en-
hanced insulin secretion, and that insulin was sufficient to
activate L-PK transcription, we next investigated whether
ChREBP silencing would interfere with insulin activation
of L-PK transcription. Indeed, as shown in Fig. 4D, the in-
Fig. 2. ChREBP and sterol-responsive element binding protein-1c (SREBP-1c) are both required for
glucose-induced fatty acid synthase (FAS) promoter activity. A, B: MIN6 cells were microinjected with
antibodies against ChREBP (a-ChREBP) (A), SREBP-1c (a-SREBP-1c) (B), or normal IgGs, as indicated,
together with FAS promoter-driven firefly luciferase reporter gene construct (pFAS.LucFF) and CMV
promoter-driven Renilla reniformis luciferase reporter gene construct (pRL.CMV) as internal standard. The
cells were cultured for 24 h in normal medium after microinjection, then switched to 3 mM glucose for 16 h
and incubated for a further 6 h at 3 or 30 mM glucose, as indicated, before imaging and photon counting.
C: MIN6 cells were transfected with anti-ChREBP specific or scrambled siRNAs, as indicated, and cultured as
in Fig. 1D before quantitative real-time RT-PCR assay using SYBR Green as described in Materials and
Methods. D: MIN6 cells were infected with SREBP dominant negative (SREBP-DN) adenovirus for 24 h
before culturing in 3 mM glucose for 16 h followed by 6 h at 3 or 30 mM glucose, as indicated, before
quantitative real-time RT-PCR assay using SYBR Green. Data are means 6 SEM from a minimum of three
separate experiments.
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duction by insulin of L-PK mRNA at low glucose concen-
tration was blunted following ChREBP knockdown. On the
other hand, overexpression of the constitutively active
nuclear fragment of SREBP-1c had no effect on L-PK pro-
moter activity (Fig. 4E), nordid theoverexpressionofdomi-
nant negative SREBP-1c affect L-PK mRNA levels (Fig. 4F).
ChREBP, but not SREBP-1c, binds to the L-PK promoter
in a glucose-dependent but insulin-independent manner in
living cells
The carbohydrate-responsive element (ChoRE) of the
L-PK promoter is well characterized and is centered at
177 bp on the mouse promoter (Fig. 5A, underlined)
(33). ChIP assay revealed that ChREBP bound directly to
this segment of the L-PK promoter at 30 but not 3 mM
glucose. In contrast, chromatin immunoprecipitation
using anti-USF2 or anti-SREBP-1c antibodies failed to
pull down this segment of the L-PK promoter (Fig. 5B). To
determine whether insulin stimulated L-PK promoter ac-
tivity directly through ChREBP binding, we performed a
ChIP assay using ChREBP antibody at low and high glu-
cose, and in the presence or absence of 1 nM insulin, or
while inhibiting insulin release with the hyperpolarizing
agent diazoxide. As shown in Fig. 5C, the addition of 1 nM
insulin to MIN6 cells cultured at low glucose did not cause
any increase in ChREBP binding, although this maneuver
resulted in the stimulation of L-PK gene expression as as-
sessed by quantitative RT-PCR (Fig. 4D). However, in-
hibition of glucose-induced insulin secretion with 100 mM
diazoxide completely abolished ChREBP binding at high
glucose (Fig. 5C).
DISCUSSION
ChREBP is a key regulator of lipogenic genes in the b cell
We have previously demonstrated that SREBP-1c is an
important regulator of lipogenesis in b cells (11, 12).
Thus, overexpression or inactivation of SREBP-1c strongly
modulates the ACC1 (pII) promoter (11). We show here
that SREBP-1c inhibition, achieved through antibody
microinjection of adenoviral overexpression of SREBP-
DN, also abolishes the induction by glucose of FAS pro-
moter and mRNA levels in MIN6 cells (Fig. 2). By contrast,
SREBP-1c overexpression and inhibition had no effect on
L-PK transcription at either low or high glucose concen-
trations (Fig. 4E, F), implying a role for other transcription
factor(s) in the response of the latter gene to glucose.
ChREBP is emerging as a key regulator of lipogenic genes
in the liver. Very recently, ChREBP-deficient mice were
intercrossed with ob/ob mice, and the resulting offspring
had a better metabolic profile, as well as decreased ap-
Fig. 3. ChREBP and SREBP-1c directly bind to the FAS promoter in a glucose-dependent manner in vivo.
A, B: MIN6 cells were incubated in 3 mM glucose for 16 h and for a further 6 h at 3 or 30 mM glucose,
as indicated, before a chromatin immunoprecipitation (ChIP) assay was performed as described in Ma-
terials and Methods using antibodies against upstream stimulatory factor-2 (USF2) (a-USF2), SREBP1-c
(a- SREBP1-c), or ChREBP (a-ChREBP), as indicated in the figures. The left panels show the primers used
(arrows) and the sequence amplified by PCR. The consensus E-boxes and sterol-responsive element site are
also indicated. The right panels show the resulting PCR products using the input fractions (i) and following
immunoprecipitation with the specific antibodies (ab) at either 3 or 30 mM glucose. Data are representative
of three independent experiments.
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petite and adiposity, suggesting a role for ChREBP in
peripheral tissues, including the brain (34). We show here
that overexpression of ChREBP potentiates the effects of
glucose on the L-PK promoter in b cells (Fig. 4B), con-
sistent with previous findings in INS-1 cells (13) as well as
hepatocytes (3). However, we now report for the first time
that inactivation of ChREBP, achieved by RNA silencing or
antibody microinjection, inhibits the induction of L-PK
by glucose in b cells (Fig. 4A, C).
Using direct ChIP assay, we also provide the novel ob-
servation that in MIN6 cells, glucose signaling promotes
binding of ChREBP to the carbohydrate response element
of the L-PK promoter. By contrast, neither SREBP-1c nor
USF binding to this site was observed at either high or low
glucose concentrations (Fig. 5). These findings would
appear to question earlier results from this laboratory
implicating USF as an important regulator of the L-PK
gene in b cells (15), possibly reflecting the uncertain
specificity of the antibodies used in these earlier microin-
jection studies, but they are consistent with the findings of
Kaytor, Shih, and Towle (35), who argue against a role for
USF in the regulation of L-PK gene expression in the liver,
and the findings of Wang and Wollheim (13) in INS-1
cells. We propose that in b cells, the absence of ChREBP
binding to the L-PK ChoRE at low glucose concentrations
may be explained by both nuclear exclusion (Fig. 1A) and
posttranscriptional modifications, as in hepatocytes (6, 8).
However, in contrast to the liver system, the actions of
Fig. 4. ChREBP, but not SREBP-1c, mediates glucose responsiveness of the liver-type pyruvate kinase (L-
PK) promoter in MIN6 cells. A, B, E: MIN6 cells were microinjected with normal IgG or anti-ChREBP
antibodies (a-ChREBP) (A), with pcDNA3 or pChREBP (B), or SREBP-CA (E), as indicated, together with
pLPK.LucFF and pRL.CMV plasmids before incubation and photon counting as in Fig. 2. C, D, F: MIN6 cells
were transfected with scrambled or specific ChREBP siRNAs (C, D) or infected with control or SREBP-DN
adenovirus (F), cultured for 24 h in normal medium, then incubated in 3 mM glucose for 16 h and
stimulated with 3 or 30 mM glucose, as indicated, for another 6 h before RNA extraction and real-time RT-
PCR assay using TaqMan, as described inMaterials andMethods. Data are means6 SEM from aminimum of
three separate experiments.
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glucose on L-PK expression in MIN6 cells are in large part
mediated by the secretion of insulin (32). Although in-
sulin is not sufficient to promote ChREBP binding to the
L-PK promoter in vivo (Fig. 5C), insulin stimulates the L-
PK promoter at low glucose concentrations and ChREBP is
necessary for insulin stimulation of the L-PK promoter
(Fig. 4D). Also, inhibiting glucose-induced insulin secre-
tion by the use of diazoxide prevents ChREBP binding on
the L-PK promoter (Fig. 5C). The latter observation could
suggest a role for changes in intracellular free Ca21 con-
centrations in the activation of ChREBP, although more
experiments are needed to confirm this hypothesis. Alter-
natively, insulin could be necessary for binding or ac-
tivation of a distinct transcription factor that works in
conjunction with ChREBP. Further work is required to
determine the respective roles of intracellular glucose
metabolism, insulin release, and the activation or inhibi-
tion of protein kinases [e.g., PKA, AMPK, Calmodulin
Kinase kinase (CamKK)] in modulating the subcellular
localization of ChREBP and its transcriptional activity in
the pancreatic b cell.
In contrast to the L-PK gene, we demonstrate here that
both ChREBP and SREBP-1c are necessary for the glucose
responsiveness of the FAS promoter (Fig. 2). Moreover,
both ChREBP and USF2 bound to both stretches of the
FAS promoter examined (containing the 65 and 332
E-boxes, Fig. 5), ChREBP in a glucose-dependent manner
and USF2 constitutively. The apparent increase in inten-
sity following immunoprecipitation with anti-USF2 ob-
served at high glucose was not always observed between
Fig. 5. ChREBP binds to the L-PK promoter in a glucose- and calcium-dependent but insulin-independent
manner in vivo. MIN6 cells were incubated for 16 h at 3 mM glucose and then for 6 h at either 3 or 30 mM
glucose, in the presence or absence of 1 nM insulin and 100 mM diazoxide, as indicated, before cross-linking
and ChIP assay as in Fig. 3. A: The primers (arrows) and the amplified sequence of the mouse L-PK promoter
by PCR are shown. The carbohydrate-responsive element is underlined. B, C: Shown are the resulting PCR
products following immunoprecipitation using anti-USF2 (a-USF2), anti-SREBP (a-SREBP), or anti-ChREBP
(a-ChREBP) antibodies as indicated. i, input fraction; ab, antibody fraction. Data are representative of three
independent experiments.
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our replicates. SREBP-1c also bound to the FAS promoter
in response to elevated glucose concentrations, but only to
the more proximal segment containing the 65 E-box.
The elegant work of Sul et al. (36), using in vivo chromatin
immunoprecipitation from extracts of livers of transgenic
mice harboring various truncations and mutations of an
FAS promoter CAT reporter gene construct, showed that
SREBP-1c binds only to the 150 sterol response element
(SRE) and not to the 65 region containing an E-box and
an overlapping SRE (shown in Fig. 3B). The resolution of
the ChIP method is largely dependent on the fragment
size obtained on shearing the chromatin, rather than on
the primer sites chosen for PCR. Although the 150 SRE
site is theoretically excluded from our ChIP assay, it is
located just outside our 135 primer and may have been
pulled down during immunoprecipitation using the
SREBP1 antibody. It is also possible that the transcription
factor recruitment might be different in b cells compared
with liver.
Taken together, these results suggest an important role
for ChREBP in b cell failure due to lipid accumulation
secondary to chronic high glucose exposure through ac-
tivation of lipogenic genes, because ChREBP silencing
decreases triglyceride content at both basal and elevated
glucose concentrations (Fig. 1E), and increases insulin
secretion at high glucose concentrations (Fig. 1F). How-
ever, although MIN6 cells are a nice in vitro model, more
work is needed to confirm a role for ChREBP in gluco-
lipotoxicity in primary islets in vivo.
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